4. CINSW Goals for Translational Cancer Research Centres: • Facilitate the generation of practice improving research and its more rapid adoption for improved patient outcomes. • Facilitate evidence into practice research. • Facilitate the more efficient and effective incorporation of research in: • Clinical training • Education • Service delivery • Within formal governance structure that supports networks and enhanced collaboration • 4. Build capacity in research and improve competitive advantage in securing other funds.

5. SYDNEY VITAL Vision: Establish Sydney Vital as a competitive network of excellence in conducting collaborative translational research to improve patient outcomes. Mission: Encourage and promote innovation and collaboration among preclinical and clinical researchers to support cancer research across the translational research pipeline.

6. SYDNEY VITAL GOALS Making sure the right patient gets the right treatment at the right time and at the right cost as a result of the translational research. Self sustainable by 2019. Enhance collaborations. Develop and maintain essential research infrastructure. Build a process to link the right people to do research. Facilitate comprehensive research training and educational programs Identify process disseminate research findings and support the implementation of evidence into practice in an efficient manner. Standardise process to identify right questions that align with health priorities. Leverage funding opportunities and increase competitive advantage Build a supportive governance structure

8. Sydney Vital Management Vision

9. SYDNEY VITAL TRANSLATIONAL Cancer RESEARCH PLAN T3 T2 T1 POLICY & PRACTICES CLINICAL SERVICES IMPLEMENTATION SCIENCE CLINICAL SCIENCE BASIC SCIENCE TRANSLATIONAL SCIENCE Flagship 1 Flagship 2 Flagship 3 Flagship 4 Pillar 1 Pillar 2 Pillar 5 Pillar 3 Pillar 4

10. FUNDING 2014-2019 Centre Funding by CINSW $ 5,836, 957 Centre Co-Funding by Usyd $ 1,000, 000 Centre Co-Funding by MCQ $ 150,000 80% research infrastructure and direct research support 20% admin (2.6FTE Administration)

11. Capacity Building 9 Research Scholars 5 Pillar initiatives # Seed Funding Research Infrastructure SV supports 2.0 FTE Bio-banking Officers Kollingbiobank Pathology research platform SV supports 0.3 FTE research pathologist. Proteomics & Genomics Incl. next gen sequencing Bioinformatics

13. Flagship 1 Investigation of novel insulin-like growth factor (IGF)-and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer (T1-T2). Flagship Lead Rob Baxter Stephen Clarke, Chief Investors Debbie Marsh, Fran Boyle, Anthony Gill Mark Molloy Proposal Title: Investigation of novel insulin-like growth factor (IGF)- and sphingosine kinase (SphK)-targeted therapies for ER-negative, therapy-resistant breast cancer. Aleksandra Ochnik R. Fellow

14. Flagship 2 NETwork (multidisciplinary management of Neureondocrine Tumors (T1-T2-T3). Dale Bailey Flagship Lead Alexander Engel Stephen Clarke Chief Investigators Anthony Gill Debbie Marsh R. Fellow Project Title: Professionalising the Multidisciplinary team Meetings in Neureondocrine Tumours (T1-T2-T3) David Chan

15. Flagship 3 Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely (T2-T3). Fran Boyle Flagship Lead Debbie Marsh Chief Investigators Stephen Clarke Mark Molloy Proposal Title: Development and pilot implementation of an evidence-based clinical pathway and toolkit for survivorship care in young women with breast cancer at high risk of stopping endocrine therapy prematurely. Haryana Dhillon R. Fellow

16. Flagship 4 Nano Medicine in Oncology: improved preoperative staging and better understanding of chemotherapy delivery (T1-T2-T3). Flagship Lead: Alexander Engel CIs Zdenka Kuncic EwaGoldys Dale Bailey R. Fellow Robert Knox

17. Pillar 1 Defining and achieving state of the art cancer diagnosis and treatment. Dale Bailey Chief Investor Anubhav Mittal Pillar Leaders Christopher Krisp

18. Pillar 2 Determining why and when early stage cancer recurs. Chief Investor Viive Howell Helen Wheeler Nham Tran Pillar Leaders Connie Diakos Kelly Charles Emily Colvin

19. Pillar 3 Understanding and overcoming mechanisms of resistance in tumours. Debbie Marsh Chief Investor Pillar Leaders Helen Wheeler Nham Tran Connie Diakos Kelly Charles Emily Colvin

20. Pillar 4 Supportive care, end-stage tumours, and end-of-life management. Chief Investor Fran Boyle, Josephine Clayton Pillar Leaders Melanie Lovell

21. Pillar 5 Hereditary Cancer Syndromes. Anthony Gill Chief Investigator MahtabFarzin Angela Chou Pillar Leaders Michelle Houang DrCrook (no picture)

24. Sydney Vital Grant Station Grant Calendar Grant development Ensuring projects are “grant ready” Grant writing resources Grant News and Updates